Illumina, Inc. $ILMN Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 190.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,812,928 shares of the life sciences company’s stock after acquiring an additional 1,188,004 shares during the quarter. Wellington Management Group LLP’s holdings in Illumina were worth $318,767,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the business. Elyxium Wealth LLC purchased a new position in shares of Illumina during the 4th quarter worth $25,000. Laurel Wealth Advisors LLC acquired a new position in Illumina during the 4th quarter worth about $26,000. Fiduciary Financial Advisors purchased a new position in Illumina during the 2nd quarter valued at about $26,000. Keating Financial Advisory Services Inc. acquired a new position in Illumina in the 2nd quarter valued at about $32,000. Finally, Quarry LP acquired a new position in Illumina in the 3rd quarter valued at about $32,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Illumina

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,799,688 shares of company stock worth $379,517,231. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Stifel Nicolaus increased their target price on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group increased their target price on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a report on Monday, August 3rd. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $188.40.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Illumina Stock Performance

Shares of ILMN opened at $215.59 on Monday. The stock has a 50 day moving average price of $194.05 and a 200 day moving average price of $155.87. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $32.55 billion, a price-to-earnings ratio of 40.22, a price-to-earnings-growth ratio of 3.03 and a beta of 1.44. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the firm posted $1.19 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.